Cost Effectiveness of Combination Therapy with Pioglitazone for Type 2 Diabetes Mellitus from a German Statutory Healthcare Perspective

Author： Neeser K.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.22, Iss.5, 2004-01, pp. : 321-341

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pioglitazone: a valuable component of combination therapy for type 2 diabetes mellitus

By Papanas Nikolaos   Katsiki Niki   Hatzitolios Apostolos I   Maltezos Efstratios  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 10, 2011-07 ,pp. : 1457-1461

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone is Effective Therapy for Elderly Patients with Type 2 Diabetes Mellitus

By Rajagopalan R.   Perez A.   Ye Z.   Khan M.   Murray F.T.  

Drugs & Aging, Vol. 21, Iss. 4, 2004-01 ,pp. : 259-271

Adis International

Access to resources Recommend Favorite

Combination lipid therapy in type 2 diabetes mellitus

By Vergèès Bruno  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 9, 2011-06 ,pp. : 1393-1403

Informa Healthcare

Access to resources Recommend Favorite

Pioglitazone combination therapy good value in type 2 diabetes

By  

Inpharma, Vol. 1, Iss. 1434, 2004-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Fixed-dose combination therapy for type 2 diabetes: sitagliptin plus pioglitazone

By Bailey Clifford J   Green Brian D   Flatt Peter R  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 8, 2010-08 ,pp. : 1017-1025

Informa Healthcare

Access to resources Recommend Favorite